The Jewish General Hospital

New 27,000-square-foot manufacturing facility now in operation to produce therapeutic Magnetodrones MONTREAL, June 25, 2024 /PRNewswire/ -- In a significant stride for cancer treatment, Starpax Biopharma Inc. ("Starpax") today unveiled its Starpax Cancer Treatment Platform™, a groundbreaking innovation that marks a monumental achievement in the company's journey towards pioneering new frontiers in cancer treatment. With a 100% remission rate and no side effects in all the subjects of the company's preclinical trials, this technology is conceived to address all solid tumors, representing 90% of cancer and 89% of deaths. The Starpax technology is addressing a major resistance problem to treatment that chemotherapy and immunotherapy haven't solved for over a century. Studies have demonstrated that 90% of the volume of a tumor receives little or no drug at all. Drugs or immune cells don't swim; they need blood vessels to be distributed in a tumor and reach cancer cells, yet blood vessels and lymphatics in a tumor become chaotic, malfunctioning, or collapse. More studies have also demonstrated that as little as 1% of the dose of systemic chemotherapy, such as nanocarriers, antibodies, and precision target drugs, reach a tumor, leaving 99% of the toxic doses free to circulate in the patient's body, attacking healthy organs and creating unwanted side effects. The Starpax Magnetodrones™ are the first component of the Starpax Cancer Treatment Platform™. They are living, self-propelled, non-pathogenic bacteria that carry anticancer drugs on their surface and are sensitive to magnetic fields. They are injected directly into a tumor and can swim in tumors without using blood vessels or circulating in the bloodstream. The Starpax PolarTrak® is the second component of the platform. It is a proprietary medical device in which the patient is installed. It generates unique magnetic fields to keep the Magnetodrones captive inside the tumor, preventing them from escaping into the rest of the patient's body and forces the Magnetodrones to spread throughout the whole volume of the tumor, including in hypoxic zones where the cancerous stem cells are located. The process is managed by the Polartrak artificial intelligence, based on the data of the patient's tumor taken from the MRI imagery scanner days before the treatment. Magnetodrones have faced over 800 mutations in the laboratory and therefore are able to detect low levels of oxygen in the tumor's hypoxia areas where the stem cells are located. Then, they penetrate and accumulate in these areas to introduce the anticancer therapeutic. "Our breakthrough Starpax platform can save countless lives, offering new hope in the fight against cancer," said Michael Gareau, Founding President of Starpax. "The unveiling of the Starpax Magnetodrones and PolarTrak lays the foundation for the future of cancer treatment. These technologies are not merely company milestones but keystones in developing solutions that completely transform the way we treat cancer today." Direct delivery and spread of anticancer therapeutics into tumors increases efficacy and minimizes damage to healthy tissues. Compared to modern systemic treatments, Starpax's technology allows the administration of up to 50 times more drug directly in the tumor, including hard-to-reach hypoxic zones. By focusing treatment specifically on the tumor, Starpax's technology significantly lowers the risk of adverse effects. It allows 800 times fewer toxic molecules to be introduced into the body than standard chemotherapy treatments, drastically reducing toxicity and side effects. The two-part platform of Magnetodrones and PolarTrak creates a safer, more effective alternative to traditional treatments, promising a significant leap in patient care and recovery. Dr. Gerald Batist, Director of Segal Cancer Center at Jewish General Hospital, stated, "Finally, with the Starpax technology, we have bacteria that actually move towards and can be accumulated in the hypoxic zone. This represents a big step in responding to a challenge that has been there and persists resistance to treatment." To manufacture the Starpax Magnetrodrones, the company has also announced its new facility in Montreal is now in operation. When fully operational, the 27,000-square-foot facility has the capacity to produce Magnetodrones to treat 10,000 patients annually. A second Magnetodrones manufacturing plant is being discussed, with a capacity of 110,000 patients annually. Starting with two patents in 2017, Starpax now holds 57 key patents and pending patents for its Magnetodrones and PolarTrak, as well as the interventional procedure ensuring a competitive edge in the field. Since its founding, Starpax has collaborated with top cancer research institutions, including McGill University, Jewish General Hospital, Polytechnique Montréal, and TransMedTech Institute. In September 2023, the company announced a $24 million Regulation A+ capital raise. It will begin clinical trials in 2025. About Starpax Biopharma Inc. Starpax Biopharma Inc. is a biopharma tech company that unites four scientific disciplines: biochemistry, microbiology, electromagnetism engineering, and artificial intelligence to create a never-before-seen technology that is transforming cancer treatment. Its technology aims to overcome the major hurdles of systemic treatments and precisely reach cancer cells throughout tumors, including hypoxic zones, without circulating in the bloodstream, thereby avoiding side effects. To learn more, visit . Media Contact Leigh Brandt [email protected] SOURCE Starpax Biopharma, Inc.

Recipients establish the benchmark for scientific advancements that enhance human health NEW YORK, June 21, 2024 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, today announced the winners for the 2024 International Prix Galien Awards and Prix Galien Italy Awards, hosted on June 20 at the Parco dei Principi Grand Hotel, in Rome. Continue Reading (PRNewsfoto/The Galien Foundation) "We are honored to host the Prix Galien Italy and International Prix Galien in tandem, bringing together the most forward-thinking innovators across the life sciences here in Italy, and across the world," said Pr. Pier Luigi Canonico, Chair of the Prix Galien Italy and International Prix Galien Awards Committee. "It is thrilling to welcome those who have excelled in the pursuit of scientific advancement to the global stage, and we look forward to seeing their continued success as Prix Galien alumni." Awards for "Advanced Therapy Medicinal Products," "Best Biological Drug," "Best Chemical Synthesis Drug," "Best Chemical-Biotechnological Drug," "Best Orphan Drug," "Best Real-World Evidence," and "Best Vaccine" were presented to industry leaders dedicated to innovation that improves the human condition. In addition to awarding this year's Prix Galien Italy winners, the International Prix Galien Award winners were selected from laureates who were previously awarded a national Prix Galien in 2022 and 2023. Winners were selected across the following categories: "Best Biotechnology Product," "Best Digital Health Solution," "Best Medical Technology," "Best Pharmaceutical Product", and "Best Vaccine." "The Galien Foundation is dedicated to uplifting talent in the life sciences industries and rewarding landmark achievements across a vast range of complex and challenging medical fields. As we kick off the summer season, the Prix Galien Italy and International Prix Galien provide us with an opportunity to celebrate a summer of therapeutic innovation," said Bruno Cohen, Chairman of The Galien Foundation. "We extend our utmost gratitude to our 2024 International Prix Galien and Prix Galien Italy winners who have proven that continued perseverance, dedication, and innovation for the future of healthcare is paving the way forward for us all." The International Prix Galien Awards is organized once every two years, inviting candidates who have previously won a National Prix Galien award during the two years preceding the International Awards ceremony. The next International Prix Galien will be hosted in March 2026, in New Delhi. The 2024 International Prix Galien Award Winners International Prix Galien Awards Committee Italy – PR PIER LUIGI CANONICO Committee Chair, Professor Emeritus of Pharmacology, Università del Piemonte Orientale Amedeo Avogadro Africa – PR AWA MARIE COLL SECK Chair, Galien Africa; Former Senior Minister to the President of the Republic of Senegal, Former Minister of Health Belgium – Luxembourg – PR JAN DE HOON Professor in Pharmacology / Clinical Pharmacology, UPC KULeuven Canada – PR ERNESTO L. SCHIFFRIN Physician-in-Chief, Department of Medicine, Jewish General Hospital; Director, Hypertension and Vascular Research Unit, Lady Davis Institute for Medical Research; Distinguished James McGill Professor and Associate Chair, Department of Medicine, McGill University France – Dr ANNICK TIBI Head of Clinical Trials Department, AGEPS, AP-HP; Associate Professor – Head of UP "Pharmaceutical Development and Innovation," Faculty of Pharmacy, University of Paris Germany – PR ERLAND ERDMANN Professor Emeritus, University of Cologne | UOC - Division of Cardiology, Pneumology, Angiology and Intensive Care, Köln Greece – PR GEORGES P. CHROUSOS Professor, School of Medicine, National and Kapodistrian School of Athens India – PR MANJU SHARMA Former Secretary to the Government of India, Department of Biotechnology; Chair New Initiative, NASI, Allahabad The Netherlands – PR DR KOOS BURGGRAAF CEO, Centre for Human Drug Research; Professor, Division of Pharmacology Leiden Academic Centre for Drug Research, University of Leiden PR DR LISETE VAN GEMERT-PIJNEN Full Professor Persuasive Health Technology, University of Twente, and Visiting Professor, University of Waterloo Poland – PR CEZARY SZCZYLIK Polish Professor of Medical Science Specializing in Oncology, Hematology and Internal Diseases Switzerland – PR CHRISTOPH RENNER Professor of Hematology - General Internal Medicine - Medical Oncology United Kingdom – PR SIR MUNIR PIRMOHAMED David Weatherall Chair of Medicine, University of Liverpool; NHS Chair of Pharmacogenetics United States of America – PR MICHAEL ROSENBLATT Former Dean of Tufts University School of Medicine, Former Chief Medical Officer of Merck & Co. Inc. The 2024 Prix Galien Italy Award Winners The 2024 Prix Galien Italy Special Mentions Prix Galien Italy Awards Committee PR PIER LUIGI CANONICO Committee Chair, Professor Emeritus of Pharmacology, Università del Piemonte Orientale Amedeo Avogadro PR ALBERTO CORSINI Università degli Studi di Milano PR ANNAMARIA DE LUCA Università degli Studi di Bari Aldo Moro PR MAURIZIO D'INCALCI Humanitas University Milano PR TULLIO FLORIO Università degli Studi di Genova PR MARIAGRAZIA GRILLI Università degli Studi del Piemonte Orientale PR CARLO RICCARDI Università degli Studi di Perugia PR MARIA ANGELA SORTINO Università di Catania PR MAURIZIO TAGLIALATELA Università Vanvitelli di Napoli PR LUIGIA TRABACE Università degli Studi di Foggia PR STEFANO VELLA Università Cattolica del Sacro Cuore, Roma About The Galien Foundation The Galien Foundation fosters, recognizes, and rewards excellence in scientific innovation to improve the state of human health. Our vision is to be the catalyst for the development of the next generation of innovative treatments and technologies that will impact the state of medical practice and save lives. The late Professor Elie Wiesel, 1986 Peace Nobel Laureate, is The Honorary Founding President of The Galien Foundation The Foundation oversees and directs activities in the US for the Prix Galien, an international awards program dedicated to progress through innovative medicines development, with chapters in 14 countries, Africa and an inaugural chapter established in India in 2024. The Prix Galien was created in 1970 by Roland Mehl in honor of Galen, the father of medical science and modern pharmacology. Worldwide, the Prix Galien is regarded as the equivalent of the Nobel Prize in biopharmaceutical research. For more information, visit . Follow the Foundation on social media: Media Contact: Kara Bradley Finn Partners [email protected] +1 646-213-7243 SOURCE The Galien Foundation

The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s R&D strategy. Lyon (France), June 20, 2024 AUROBAC THERAPEUTICS, a biopharmaceutical company founded by Boehringer Ingelheim, bioMérieux and Evotec, today announced the creation of its Scientific Advisory Board (SAB) and the appointment of its members. Comprised of distinguished experts in preclinical and clinical drug development, diagnostics, and infectious diseases, the SAB will provide scientific and medical expertise as well as strategic guidance to support AUROBAC’s R&D strategy and to help advance its first products to clinical trials. The SAB duties will also include program execution considerations in the framework of innovation, clinical and market dynamics. “We are thrilled to welcome such a qualified and experienced group of experts to our Scientific Advisory Board”, said Florence Séjourné, CEO of AUROBAC THERAPEUTICS. “Their collective expertise and insights will be invaluable as we navigate the complexities of developing innovative products targeting bacterial infections, antimicrobial resistance and their consequences in acute hospital settings. The creation of the SAB is a significant milestone for AUROBAC, underscoring our commitment to scientific excellence and innovation.” The newly formed SAB will be chaired by Dr. Marco Taglietti, who is also an Independent Member of AUROBAC’s Board, and consists of: Sujata M. Bhavnani, PharmD, M.S., is a distinguished pharmacokinetics-pharmacodynamics expert for antimicrobial agents. Her work has supported decisions for dose selection and interpretive criteria for the in vitro susceptibility testing for numerous new drug applications. She is the Executive Vice-President of Translational Medicine for ICPD (Institute for Clinical Pharmacodynamics). She received her Pharm.D. from the Albany College of Pharmacy, completed a two-year post doctorial fellowship in infectious diseases and pharmacokinetics at Millard Fillmore Hospital, and her M.S. in biometry from the University at Buffalo.Mark Miller, MD, is a renowned medical clinician, microbiologist and clinical researcher with expertise in infectious disease and epidemiology. Until recently, he was Chief Medical Officer, Executive Vice-President and was on the Executive Management Committee at bioMérieux for 11 years (2012 – 2024). Prior to bioMérieux, he was Head of Infectious Diseases, Chief of Clinical Microbiology, and Chair of Infection Prevention and Control at the Jewish General Hospital (Montreal, Canada) for over 25 years, until 2012. He received his MD with further specialization in Internal Medicine, Infectious Diseases and Medical Microbiology and his M.Sc. in Epidemiology and Biostatistics from McGill University (Montreal, Canada) where he was appointed a Full Professor of Medicine in 2012.Manu Shankar-Hari, MD, Ph.D., M.Sc., is a clinician scientist with an outstanding expertise in translational research and immunology of sepsis. Currently, he holds the Personal Chair of Translational Critical Care Medicine at the Institute for Regeneration and Repair (University of Edinburgh). He leads a globally unique precision medicine program for critically ill adults to enable targeted immunomodulation (The TRAITS programme). For additional details of Prof Shankar-Hari’s research, please see academic webpage.Ruben Tommasi, Ph.D., has extensive expertise in preclinical development with almost 30 years’ of industry and biotech experience. He is currently Chief Scientific Officer of Dunad Therapeutics since 2022. Prior to Dunad, he was a founding leader and Chief Scientific Officer at Entasis Therapeutics (2015 – 2022). He also spent 4 years at AstraZeneca as Executive Director, Chemistry, of the Infection Innovative Medicines unit, after having been at Novartis for 17 years where he led several medicinal chemistry efforts, most recently the Infectious Disease Therapy unit. He received a Ph.D. in organic chemistry from the State University of New York at Albany.Richard G. Wunderink, MD, is a highly-experienced clinician scientist, active in pulmonary infections and sepsis. He is a professor of medicine in the Pulmonary and Critical Care Division of Northwestern University’s Feinberg School of Medicine and formerly medical director of the MICU, Northwestern Memorial Hospital. He co-chaired the 2007 IDSA (Infectious Diseases Society of America) / ATS (American Thoracic Society) Consensus Guidelines Committee on the management of community-acquired pneumonia. He was a member of previous ATS/IDSA guidelines committee on HAP/VAP and the ERS/ESCIM/ESCMID/ALAT International Guidelines for the Management of HAP/VAP and the recently published ERS/ESCIM/ESCMID/ALAT guidelines for management of Severe CAP. He received his MD from the Indiana University School of Medicine. “I am honoured to take on the role of Chairman of AUROBAC's SAB and look forward to working together with these esteemed scientists to support the development of products addressing antimicrobial resistance, one of the biggest public health threats of our time”, said Dr. Marco Taglietti, Chairman of the SAB. Leveraging the invaluable expertise of the SAB, the AUROBAC team is well prepared to advance its product pipeline and provide effective treatments for patients with severe bacterial infections. About AUROBAC THERAPEUTICS: AUROBAC THERAPEUTICS is a biopharmaceutical company founded in 2022 by three highly renowned life sciences innovation companies, Boehringer Ingelheim, Evotec and bioMérieux. Dedicated to addressing high unmet medical needs associated with infections in acute hospital settings, amidst the growing antimicrobial resistance (AMR) epidemic, AUROBAC is advancing a robust pipeline. This includes ATX101, a potential first-in-class therapeutic targeting the loss of vascular integrity in septic shock, developed in collaboration with Boehringer Ingelheim, and ATX401, an engineered lysin with potent activity against multiple clinically relevant Gram-negative bacteria. Additionally, the company’s unique drug discovery engine aims to identify new precision antimicrobials, as showcased through a collaboration with GENERARE Bioscience. Contact: Julie Cervesi, Head of Business Development - Mail: contact@aurobac-tx.comWebsite: aurobac-tx.comLinkedin: https://linkedin.com/company/aurobac-tx/X: https://x.com/AurobacTX